德琪醫藥(06996.HK):Selinexor治療骨髓纖維化臨牀申請獲受理
德琪醫藥(06996.HK)宣佈,旗下口服型XPO1抑制劑塞利尼索(selinexor),用於單藥治療骨髓纖維化(MF)患者的二期臨牀試驗,已獲得中國國家藥品監督管理局受理。
該試驗爲一項隨機、開放性、多中心臨牀研究,在接受過至少6個月JAK1/2抑制劑治療的MF患者中評價塞利尼索與醫生選擇治療對比的安全性和療效,計劃在全球啓動約75家研究中心。
德琪醫藥創始人、董事長兼首席執行官梅建明表示,將在藥監局的監管下積極推進研究。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.